Supplemental material
Current Medical Research and Opinion
Volume 36, 2020 - Issue 5
Related Research Data
Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review
Source:
Springer Nature
Restoring function in major depressive disorder: A systematic review.
Source:
Elsevier BV
Psychosocial impairment and recurrence of major depression
Source:
Elsevier
Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
Source:
Physicians Postgraduate Press, Inc
Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Source:
Elsevier BV
Risk factors and predictors of compliance in depression
Source:
Elsevier BV
Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
Source:
Informa UK Limited
Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder
Source:
Elsevier BV
A new depression scale designed to be sensitive to change.
Source:
Royal College of Psychiatrists
Incorporating Multidimensional Patient-Reported Outcomes of Symptom Severity, Functioning, and Quality of Life in the Individual Burden of Illness Index for Depression to Measure Treatment Impact and Recovery in MDD
Source:
American Medical Association (AMA)
Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.
Source:
American Psychiatric Association Publishing
Association between antidepressant side effects and functional impairment in patients with major depressive disorders.
Source:
Elsevier BV
Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study
Source:
Informa Healthcare
Depression hurts, depression costs: The medical spending attributable to depression and depressive symptoms in China.
Source:
Wiley
Remission, Recovery, Relapse, and Recurrence
Source:
American Medical Association (AMA)
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland
Source:
Informa UK Limited
The measurement of disability.
Source:
Ovid Technologies (Wolters Kluwer Health)
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Source:
Ovid Technologies (Wolters Kluwer Health)
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale
Source:
Ovid Technologies (Wolters Kluwer Health)
Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
Source:
Informa UK Limited
How should remission from depression be defined? The depressed patient's perspective.
Source:
American Psychiatric Association Publishing
What is important in being cured from depression? Discordance between physicians and patients (1).
Source:
Elsevier BV
The recovery index: A novel approach to measuring recovery and predicting remission in major depressive disorder.
Source:
Elsevier BV
Remission in depressed outpatients: more than just symptom resolution?
Source:
Elsevier BV
A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder.
Source:
Oxford University Press (OUP)
Linking provided by
